Loading...
XSTO
MCAP
Market cap770mUSD
Oct 09, Last price  
515.00SEK
1D
2.28%
1Q
2.90%
Jan 2017
1,384.15%
IPO
3,861.54%
Name

MedCap AB (publ)

Chart & performance

D1W1MN
XSTO:MCAP chart
P/E
35.09
P/S
3.66
EPS
14.68
Div yield, %
—
Shrs. gr., 5y
0.89%
Rev. gr., 5y
20.86%
Revenues
2.11b
+16.67%
188,857,000187,055,000258,787,000315,887,000336,510,000349,041,000826,086,000852,754,000816,918,000851,668,000411,200,000709,000,000757,100,000817,400,000916,300,0001,111,400,0001,587,400,0001,806,800,0002,108,000,000
Net income
220m
+5.98%
-7,727,000114,0005,797,00013,511,00010,705,00017,112,00022,608,0008,524,00019,452,00073,0002,100,000600,00053,700,00060,900,00096,500,000117,600,000172,200,000207,400,000219,800,000
CFO
343m
-4.81%
2,146,0003,373,00017,317,00030,637,00028,749,00038,550,000865,0002,258,000-14,917,00081,456,00027,300,00090,600,00071,400,000115,600,000116,300,00085,500,000228,000,000360,000,000342,700,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.

Related entities

Subsidiaries
Abilia Sverige Holding AB

Key people

Anders Dahlberg
Chief Executive Officer · since 2020
Kristina Ekblad
Chief Financial Officer · since 2020
Investment Manager · since 2022
Lars Angman
Investment Manager · since 2020
Karl Tobieson
Chairman of the Board · since 2021
Otto Ankarcrona
Independent Director · since 2023
Independent Director · since 2023
David Jern
Independent Director · since 2021
Lena Soderstrom
Independent Director · since 2022
Anna Torner
Independent Director · since 2022
IPO date
Jul 04, 2006
Employees
463
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Engelbrektsgatan 9-11
STOCKHOLM, AB 114 32
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT